Top Markets
Coin of the day
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

MyMD Pharmaceuticals, Inc.

MYMD
Rang in Aktien #35400
MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical... MyMD Pharmaceuticals, Inc. is a pharmaceutical firm currently in the clinical development stage, focused on devising diverse therapeutic strategies that target the underlying origins of various illnesses. One of its key initiatives is the development of MYMD-1, a drug platform centered on a small molecule presently undergoing clinical trials. This molecule works by regulating the immune system to suppress TNF-alpha, a major contributor to chronic inflammation, along with other pro-inflammatory cell-signaling proteins. MYMD-1 is being explored for its potential to delay aging, extend lifespan, manage autoimmune conditions, and treat depression linked to COVID-19. Furthermore, the company is advancing Supera-CBD, a synthetic version of cannabidiol, which aims to address chronic pain, addiction, and epilepsy. MyMD Pharmaceuticals was established in 2014 and its corporate headquarters are situated in Baltimore, Maryland.
Aktienkurs
$1.85
Zuletzt synchronisiert: 2024-08-19
Marktkapitalisierung
$3.96M
Veränderung (1 Tag)
2.78%
Veränderung (1 Jahr)
0.00%
Land
US
Handel MyMD Pharmaceuticals, Inc. (MYMD)

Kategorie

EPS für MyMD Pharmaceuticals, Inc. (MYMD)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von MyMD Pharmaceuticals, Inc. beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von MyMD Pharmaceuticals, Inc. von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber
Unternehmen EPS EPS-Differenz Land
$17.32 -
US
$27.74 -
NL
- -
CH
- -
KR
$13.70 -
BE